Somewhat Negative Press Coverage Somewhat Unlikely to Affect Invivo Therapeutics (NVIV) Share Price

Headlines about Invivo Therapeutics (NASDAQ:NVIV) have trended somewhat negative this week, according to Accern. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Invivo Therapeutics earned a media sentiment score of -0.06 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.9606763879363 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Separately, ValuEngine lowered Invivo Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

Invivo Therapeutics (NASDAQ:NVIV) traded down $0.02 during trading on Monday, reaching $0.83. The company had a trading volume of 180,200 shares, compared to its average volume of 260,841. Invivo Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $4.95. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $27.85, a P/E ratio of -0.98 and a beta of 3.19.

Invivo Therapeutics (NASDAQ:NVIV) last posted its quarterly earnings data on Monday, October 30th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). equities analysts anticipate that Invivo Therapeutics will post -0.81 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Negative Press Coverage Somewhat Unlikely to Affect Invivo Therapeutics (NVIV) Share Price” was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/25/somewhat-negative-press-coverage-somewhat-unlikely-to-affect-invivo-therapeutics-nviv-share-price.html.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

What are top analysts saying about Invivo Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Invivo Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit